Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Companies

In the competitive world of biotechnology and pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Celldex Therapeutics, Inc. and Evotec SE, two prominent players, have shown contrasting trends in their SG&A management from 2014 to 2023.

Celldex Therapeutics, Inc.

Celldex has maintained a relatively stable SG&A expense trend, with a slight increase of about 50% over the decade. Their expenses peaked in 2016 at approximately $36 million, then dipped, reflecting a strategic cost management approach.

Evotec SE

In contrast, Evotec SE's SG&A expenses have surged by over 800%, reaching nearly $170 million in 2023. This significant rise suggests aggressive expansion and investment in administrative capabilities.

Conclusion

While Evotec's strategy indicates growth, Celldex's steady approach highlights a focus on cost efficiency. Investors should consider these trends when evaluating the companies' financial strategies.